Post by ashiwi on Apr 22, 2014 23:06:22 GMT -5
www.gtcbio.com/conference/diabetes-drug-discovery-and-development-agenda
Andrea Leone-Bay
Vice President Pharmaceutical Research and Development
MannKind Corporation
For diabetes treatment, all currently marketed insulin and GLP-1 therapies are administered by injection. This route of delivery, while common for peptide and protein drugs, can be a barrier to the initiation of therapy and a hindrance to compliance once therapy has started. As an alternative, the oral inhalation route, comprising dry powder formulations with simple inhalers, provides a viable delivery option. At MannKind, dry powder formulations based on advanced particle engineering and patient-friendly, breath-powered inhalation devices have been integrated to simplify drug delivery by oral inhalation. This approach expands this route of delivery beyond the traditional pulmonary diseases and has been used to develop Afrezza®, an orally inhaled insulin product. This presentation will discuss three orally inhaled products designed specifically to provide options in the treatment of diabetes: inhaled insulin and GLP-1 for glucose control; and oxyntomodulin for obesity.
• Attendees will learn about inhaled insulin, GLP-1 and oxyntomodulin for diabetes treatment.
• Attendees will learn the advantages of simple, patient-friendly drug delivery by oral inhalation for diabetes treatment.
Andrea Leone-Bay
Vice President Pharmaceutical Research and Development
MannKind Corporation
For diabetes treatment, all currently marketed insulin and GLP-1 therapies are administered by injection. This route of delivery, while common for peptide and protein drugs, can be a barrier to the initiation of therapy and a hindrance to compliance once therapy has started. As an alternative, the oral inhalation route, comprising dry powder formulations with simple inhalers, provides a viable delivery option. At MannKind, dry powder formulations based on advanced particle engineering and patient-friendly, breath-powered inhalation devices have been integrated to simplify drug delivery by oral inhalation. This approach expands this route of delivery beyond the traditional pulmonary diseases and has been used to develop Afrezza®, an orally inhaled insulin product. This presentation will discuss three orally inhaled products designed specifically to provide options in the treatment of diabetes: inhaled insulin and GLP-1 for glucose control; and oxyntomodulin for obesity.
• Attendees will learn about inhaled insulin, GLP-1 and oxyntomodulin for diabetes treatment.
• Attendees will learn the advantages of simple, patient-friendly drug delivery by oral inhalation for diabetes treatment.